Diagnostic performance of breast-specific gamma imaging in the assessment of residual tumor after neoadjuvant chemotherapy in breast cancer patients
详细信息 查看全文
- 作者：Hyo Sang Lee (1)
Beom Seok Ko (2)
Sei Hyun Ahn (2)
Byung Ho Son (2)
Jong Won Lee (2)
Hee Jeong Kim (2)
Jong Han Yu (2)
Sung-Bae Kim (3)
Kyung Hae Jung (3)
Jin-Hee Ahn (3)
Joo Hee Cha (4)
Hak Hee Kim (4)
Hee Jin Lee (5)
In-Hye Song (5)
Gyungyub Gong (5)
Seol-Hoon Park (6)
Jong Jin Lee (1)
Dae Hyuk Moon (1) - 关键词：Breast ; specific gamma imaging ; Breast cancer ; Magnetic resonance imaging ; Neoadjuvant chemotherapy ; Residual tumor size
- 刊名：Breast Cancer Research and Treatment
- 出版年：2014
- 出版时间：May 2014
- 年：2014
- 卷：145
- 期：1
- 页码：91-100
- 全文大小：398 KB
- 参考文献：1. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30:96-02 CrossRef
2. Balu-Maestro C, Chapellier C, Bleuse A, Chanalet I, Chauvel C, Largillier R (2002) Imaging in evaluation of response to neoadjuvant breast cancer treatment benefits of MRI. Breast Cancer Res Treat 72(2):145-52 CrossRef
3. Weatherall PT, Evans GF, Metzger GJ, Saborrian MH, Leitch AM (2001) MRI vs. histologic measurement of breast cancer following chemotherapy: comparison with X-ray mammography and palpation. J Magn Reson Imaging 13(6):868-75. doi:10.1002/jmri.1124 CrossRef
4. Segara D, Krop IE, Garber JE, Winer E, Harris L, Bellon JR, Birdwell R, Lester S, Lipsitz S, Iglehart JD, Golshan M (2007) Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? J Surg Oncol 96(6):474-80. doi:10.1002/jso.20856 CrossRef
5. Chagpar AB, Middleton LP, Sahin AA, Dempsey P, Buzdar AU, Mirza AN, Ames FC, Babiera GV, Feig BW, Hunt KK, Kuerer HM, Meric-Bernstam F, Ross MI, Singletary SE (2006) Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg 243(2):257-64. doi:10.1097/01.sla.0000197714.14318.6f00000658-200602000-00016 CrossRef
6. Denis F, Desbiez-Bourcier AV, Chapiron C, Arbion F, Body G, Brunereau L (2004) Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer. Eur J Surg Oncol 30(10):1069-076. doi:10.1016/j.ejso.2004.07.024 CrossRef
7. Chen JH, Feig B, Agrawal G, Yu H, Carpenter PM, Mehta RS, Nalcioglu O, Su MY (2008) MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer 112(1):17-6. doi:10.1002/cncr.23130 CrossRef
8. Moon HG, Han W, Lee JW, Ko E, Kim EK, Yu JH, Kang SY, Moon WK, Cho N, Park IA, Oh DY, Han SW, Im SA, Noh DY (2009) Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment. Ann Oncol 20(4):636-41. doi:10.1093/annonc/mdn683 CrossRef
9. Loo CE, Straver ME, Rodenhuis S, Muller SH, Wesseling J, Vrancken Peeters MJ, Gilhuijs KG (2011) Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol 29(6):660-66. doi:10.1200/JCO.2010.31.1258JCO.2010.31.1258 CrossRef
10. McGuire KP, Toro-Burguete J, Dang H, Young J, Soran A, Zuley M, Bhargava R, Bonaventura M, Johnson R, Ahrendt G (2011) MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy? Ann Surg Oncol 18(11):3149-154. doi:10.1245/s10434-011-1912-z CrossRef
11. Brem RF, Schoonjans JM, Kieper DA, Majewski S, Goodman S, Civelek C (2002) High-resolution scintimammography: a pilot study. J Nucl Med 43(7):909-15
12. Spanu A, Chessa F, Meloni GB, Sanna D, Cottu P, Manca A, Nuvoli S, Madeddu G (2008) The role of planar scintimammography with high-resolution dedicated breast camera in the diagnosis of primary breast cancer. Clin Nucl Med 33(11):739-42. doi:10.1097/RLU.0b013e318187ee7500003072-200811000-00001 CrossRef
13. Weigert JM, Bertrand ML, Lanzkowsky L, Stern LH, Kieper DA (2012) Results of a multicenter patient registry to determine the clinical impact of breast-specific gamma imaging, a molecular breast imaging technique. AJR 198(1):W69–W75. doi:10.2214/AJR.10.6105198/1/W69 CrossRef
14. Park J, Lee A, Jung K, Choi S, Lee S, Bae S (2013) Diagnostic performance of breast-specific gamma imaging (BSGI) for breast cancer: usefulness of dual-phase imaging with 99?mTc-sestamibi. Nucl Med Mol Imaging 47(1):18-6. doi:10.1007/s13139-012-0176-2 CrossRef
15. Yoo C, Ahn JH, Jung KH, Kim SB, Kim HH, Shin HJ, Ahn SH, Son BH, Gong G (2012) Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in patients with breast cancer following neoadjuvant chemotherapy. J Breast Cancer 15(2):203-10. doi:10.4048/jbc.2012.15.2.203 CrossRef
16. Shin HJ, Baek HM, Ahn JH, Baek S, Kim H, Cha JH, Kim HH (2012) Prediction of pathologic response to neoadjuvant chemotherapy in patients with breast cancer using diffusion-weighted imaging and MRS. NMR Biomed 25(12):1349-359. doi:10.1002/nbm.2807 CrossRef
17. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736-747. doi:10.1093/annonc/mdr304 CrossRef
18. Goldsmith SJ, Parsons W, Guiberteau MJ, Stern LH, Lanzkowsky L, Weigert J, Heston TF, Jones E, Buscombe J, Stabin MG, Society of Nuclear M (2010) SNM practice guideline for breast scintigraphy with breast-specific gamma-cameras 1.0. J Nucl Med Technol 38(4):219-24. doi:10.2967/jnmt.110.082271 CrossRef
19. Jin S, Kim SB, Ahn JH, Jung KH, Ahn SH, Son BH, Lee JW, Gong G, Kim HO, Moon DH (2013) 18 F-fluorodeoxyglucose uptake predicts pathological complete response after neoadjuvant chemotherapy for breast cancer: a retrospective cohort study. J Surg Oncol 107(2):180-87. doi:10.1002/jso.23255 CrossRef
20. Kurosumi M (2004) Significance of histopathological evaluation in primary therapy for breast cancer—recent trends in primary modality with pathological complete response (pCR) as endpoint. Breast Cancer 11(2):139-47 CrossRef
21. Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25(28):4414-422. doi:10.1200/JCO.2007.10.6823 CrossRef
22. Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1(8476):307-10 CrossRef
23. Schillaci O, Buscombe JR (2004) Breast scintigraphy today: indications and limitations. Eur J Nucl Med Mol Imaging 31(Suppl 1):S35–S45. doi:10.1007/s00259-004-1525-x CrossRef
24. Larson M, Larson M, Li Z, Larson M, Li Z, Hall CL, Jensen E, McAllister DM, Kalyanaraman B, Zhao M (2009) Physiological fluctuation of (99m)Tc-sestamibi uptake in normal mammary glands: a systematic investigation in female rats. Acta Radiol 50(9):975-78. doi:10.3109/02841850903134127 CrossRef
25. Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A, Heys SD (2003) A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12(5):320-27 CrossRef
26. Veronesi U, Bonadonna G, Zurrida S, Galimberti V, Greco M, Brambilla C, Luini A, Andreola S, Rilke F, Raselli R et al (1995) Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg 222(5):612-18 CrossRef
27. Turnbull LW (2009) Dynamic contrast-enhanced MRI in the diagnosis and management of breast cancer. NMR Biomed 22(1):28-9. doi:10.1002/nbm.1273 CrossRef
28. Tiling R, Stephan K, Sommer H, Shabani N, Linke R, Hahn K (2004) Tissue-specific effects on uptake of 99mTc-sestamibi by breast lesions: a targeted analysis of false scintigraphic diagnoses. J Nucl Med 45(11):1822-828
29. Li SP, Padhani AR, Taylor NJ, Beresford MJ, Ah-See ML, Stirling JJ, d’Arcy JA, Collins DJ, Makris A (2011) Vascular characterisation of triple negative breast carcinomas using dynamic MRI. Eur Radiol 21(7):1364-373. doi:10.1007/s00330-011-2061-2 CrossRef
30. Keto JL, Kirstein L, Sanchez DP, Fulop T, McPartland L, Cohen I, Boolbol SK (2012) MRI versus breast-specific gamma imaging (BSGI) in newly diagnosed ductal cell carcinoma-in situ: a prospective head-to-head trial. Ann Surg Oncol 19(1):249-52. doi:10.1245/s10434-011-1848-3 CrossRef - 作者单位：Hyo Sang Lee (1)
Beom Seok Ko (2)
Sei Hyun Ahn (2)
Byung Ho Son (2)
Jong Won Lee (2)
Hee Jeong Kim (2)
Jong Han Yu (2)
Sung-Bae Kim (3)
Kyung Hae Jung (3)
Jin-Hee Ahn (3)
Joo Hee Cha (4)
Hak Hee Kim (4)
Hee Jin Lee (5)
In-Hye Song (5)
Gyungyub Gong (5)
Seol-Hoon Park (6)
Jong Jin Lee (1)
Dae Hyuk Moon (1)
1. Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Republic of Korea
2. Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
3. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
4. Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
5. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
6. Department of Nuclear Medicine, Ulsan University Hospital, Ulsan, Republic of Korea - ISSN：1573-7217
文摘
To evaluate the diagnostic performance of breast-specific gamma imaging (BSGI) in the assessment of residual tumor after neoadjuvant chemotherapy (NAC) in breast cancer patients, female breast cancer patients who underwent NAC, preoperative 99mTc-sestamibi BSGI, and subsequent definitive breast surgery were enrolled retrospectively. The accuracy of BSGI in the assessment of residual tumor presence and residual tumor size was evaluated and compared to that of magnetic resonance imaging (MRI) using pathology results as the gold standard. The sensitivity and specificity of BSGI for residual tumor detection in 122 enrolled patients were 74.0 and 72.2?%, respectively, and were comparable to those of MRI (81.7 and 72.2?%; P?>?0.100). The residual tumor size was significantly underestimated by BSGI in the luminal subtype (P?=?0.008) and by MRI in the luminal (P?<?0.001) and HER2 subtypes (P?=?0.032), with a significantly lesser degree of underestimation by BSGI than MRI in both subtypes. In the triple-negative subtype, both BSGI and MRI generated accurate tumor size measurements. The residual cellularity of triple-negative tumors was significantly higher than that of the non-triple-negative tumors (P?=?0.017). The diagnostic performance of BSGI in the assessment of residual tumor is comparable to that of MRI in breast cancer patients. The assessment of residual tumor extent by BSGI depends on the molecular subtype, but BSGI may be more accurate than MRI. Underestimation of tumor size in the luminal and/or HER2 subtypes by BSGI and MRI may be due to low-residual cellularity.